Trust Point’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$770K Buy
1,472
+679
+86% +$348K 0.06% 173
2026
Q2
$394K Buy
793
+21
+3% +$9.31K 0.03% 275
2026
Q1
$345K Buy
772
+272
+54% +$127K 0.03% 345
2025
Q4
$227K Buy
+500
New +$216K 0.02% 437
2025
Q2
– Sell
-437
Closed -$212K – 468
2025
Q1
$212K Sell
437
-738
-63% -$344K 0.02% 431
2024
Q4
$473K Buy
1,175
+59
+5% +$27.3K 0.03% 301
2024
Q3
$519K Buy
1,116
+37
+3% +$17.8K 0.04% 271
2024
Q2
$506K Buy
1,079
+22
+2% +$9.5K 0.04% 263
2024
Q1
$442K Buy
+1,057
New +$447K 0.03% 314

Other funds holding VRTX

Trust Point's VRTX Position: Q3 2026 in Review

Trust Point increased its Vertex Pharmaceuticals (VRTX) stake by 86% in Q3 2026, buying an estimated $348K and bringing the position to 1,472 shares worth $770K. The position accounts for 0.06% of the portfolio, ranked #173.

Trust Point first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Trust Point held 1,472 shares of Vertex Pharmaceuticals worth $770K as of Q3 2026.
  • Trust Point bought 679 Vertex Pharmaceuticals shares in Q3 2026, an estimated $348K.
  • Vertex Pharmaceuticals made up 0.06% of Trust Point's portfolio in Q3 2026, its #173 holding.
  • Trust Point first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.